The Accuracy of Optic Biopsies Versus Conventional Biopsies for the Diagnosis of Superficial Bladder Neoplasia

Overview

This study evaluates the accuracy of Confocal Laser Endomicroscopy (CLE) in the diagnostic of non-invasive flat and exophytic bladder neoplasia. CLE results are compared to histopathology results.

Full Title of Study: “The Accuracy of Probe-based Confocal Laser Endomicroscopy Versus Conventional Endoscopic Biopsies for the Diagnosis of Superficial Bladder Neoplasia.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: Single (Investigator)
  • Study Primary Completion Date: September 2019

Detailed Description

Confocal Laser Endomicroscopy (CLE) is a technique which during endoscopic examination of the bladder (cystoscopy) gives magnified, microscopic-like images of tissues and cells, by inserting a laser fiber through the cystoscope. CLE aims to target biopsies during cystoscopy and reduce the number of biopsies, and the need for additional cystoscopies i general anesthesia. This study evaluates the ability of CLE to assess tissue in the bladder. The ability to diagnose normal mucosa, inflammation and tumors of the bladder by the CLE is compared to the histopathological examination of selected tissues (biopsies). Patients scheduled for cystoscopy with biopsies in general anesthesia are recruited for the study. After standard cystoscopy where suspicious mucosal areas are located and marked, A contrast agent (Fluorescein) is administrated intravenously. CLE fiber is introduced through the cystoscope and the marked mucosal areas are examined by direct contact with the laser fiber. The pathologist assesses the CLE video and registers the results. Biopsies are then taken from the selected, suspicious areas. The results of CLE assessment are compared with the histopathological results.

Interventions

  • Device: Confocal LASER Endomicroscopy
    • Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital’s Pathology Department, which is affiliated CLE- study.

Arms, Groups and Cohorts

  • Other: CLE
    • CLE assessed by the pathologist
  • Active Comparator: Biopsy
    • Histology assessed by the pathologist

Clinical Trial Outcome Measures

Primary Measures

  • accordance between CLE and histology in flat bladder tumors
    • Time Frame: An average of 18 months
    • Accordance between confocal laser endoscopy and conventional biopsy according to the evaluation of the pathologist in flat bladder neoplasia
  • Accordance between CLE and histology in exophytic bladder tumors
    • Time Frame: An average of 18 months
    • Accordance between confocal laser endoscopy and conventional biopsy according to the evaluation of the pathologist in exophytic bladder neoplasia

Secondary Measures

  • Accordance between CLE assessed by the surgeon and histology.
    • Time Frame: An average of 18 months
    • Accordance between confocal laser endoscopy and conventional biopsy according to the evaluation of the surgeon in both flat and exophytic bladder neoplasia
  • Accordance between the per-operative evaluation of CLE of the pathologist and the surgeon
    • Time Frame: An average of 18 months
    • Accordance between the per-operative evaluation of CLE of the pathologist and the surgeon

Participating in This Clinical Trial

Inclusion Criteria

  • First time Transurethral Resection of Bladder (TURB) for bladder tumors under 3 cm – Suspicious mucosa / Carcinoma in situ – Recurrent pTa – Positive cytology with normal flexible cystoscopy – Control after Bacille Calmette Guérin (BCG) treatment Exclusion Criteria:

  • Allergy to fluorescein – Pregnant and lactating women. – Renal failure (eGFR <20 ml / min)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Herlev Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sami Beji, MD, Medical doctor – Herlev Hospital
  • Overall Official(s)
    • Sami Beji, MD, Principal Investigator, Herlev Hospital
  • Overall Contact(s)
    • Sami Beji, MD, 53720546, sami.beji.01@regionh.dk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.